<HashMap><database>biostudies-other</database><scores/><additional><submitter>Shin WS</submitter><funding>NCI NIH HHS</funding><pagination>29018</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4931442</full_dataset_link><abstract>We report here a tumor-targeting masked phototherapeutic agent 1 (PT-1). This system contains SN-38-a prodrug of the topoisomerase I inhibitor irinotecan. Topoisomerase I is a vital enzyme that controls DNA topology during replication, transcription, and recombination. An elevated level of topoisomerase I is found in many carcinomas, making it an attractive target for the development of effective anticancer drugs. In addition, PT-1 contains both a photo-triggered moiety (nitrovanillin) and a cancer targeting unit (biotin). Upon light activation in cancer cells, PT-1 interferes with DNA re-ligation, diminishes the expression of topoisomerase I, and enhances the expression of inter alia mitochondrial apoptotic genes, death receptors, and caspase enzymes, inducing DNA damage and eventually leading to apoptosis. In vitro and in vivo studies showed significant inhibition of cancer growth and the hybrid system PT-1 thus shows promise as a programmed photo-therapeutic ("phototheranostic").</abstract><repository>biostudies-other</repository><data_source>Europe PMC</data_source><omics_type>Unknown</omics_type><volume>6</volume><journal>Scientific reports</journal><pmcid>PMC4931442</pmcid><funding_grant_id>R01 CA068682</funding_grant_id><pubmed_authors>Shin WS</pubmed_authors><pubmed_authors>Lee GG</pubmed_authors><pubmed_authors>Sessler JL</pubmed_authors><pubmed_authors>Kim JH</pubmed_authors><pubmed_authors>Han J</pubmed_authors><pubmed_authors>Kumar R</pubmed_authors><pubmed_authors>Kim JS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Programmed activation of cancer cell apoptosis: A tumor-targeted phototherapeutic topoisomerase I inhibitor.</name><description>We report here a tumor-targeting masked phototherapeutic agent 1 (PT-1). This system contains SN-38-a prodrug of the topoisomerase I inhibitor irinotecan. Topoisomerase I is a vital enzyme that controls DNA topology during replication, transcription, and recombination. An elevated level of topoisomerase I is found in many carcinomas, making it an attractive target for the development of effective anticancer drugs. In addition, PT-1 contains both a photo-triggered moiety (nitrovanillin) and a cancer targeting unit (biotin). Upon light activation in cancer cells, PT-1 interferes with DNA re-ligation, diminishes the expression of topoisomerase I, and enhances the expression of inter alia mitochondrial apoptotic genes, death receptors, and caspase enzymes, inducing DNA damage and eventually leading to apoptosis. In vitro and in vivo studies showed significant inhibition of cancer growth and the hybrid system PT-1 thus shows promise as a programmed photo-therapeutic ("phototheranostic").</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Jul</publication><modification>2019-03-27T02:17:29Z</modification><creation>2019-03-27T02:17:29Z</creation></dates><accession>S-EPMC4931442</accession><cross_references><pubmed>27374023</pubmed><doi>10.1038/srep29018 </doi></cross_references></HashMap>